AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer

E Jensen-Jarolim; H J Bax; R Bianchini; S Crescioli; T R Daniels-Wells; D Dombrowicz; E Fiebiger; H J Gould; S Irshad; J Janda; D H Josephs; F Levi-Schaffer; L O Mahony; G Pellizzari; M L Penichet; F Redegeld; F Roth-Walter; J Singer; E Untersmayr; L Vangelista; S N Karagiannis

doi:10.1111/all.13311

AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer

E Jensen-Jarolim, H J Bax, R Bianchini, S Crescioli, T R Daniels-Wells, D Dombrowicz, E Fiebiger, H J Gould, S Irshad, J Janda, D H Josephs, F Levi-Schaffer, L O Mahony, G Pellizzari, M L Penichet, F Redegeld, F Roth-Walter, J Singer, E Untersmayr, L VangelistaS N Karagiannis

Medical University of Vienna
David Geffen School of Medicine at UCLA
INSERM, CHU Lille, European Genomic Institute of Diabetes, Institut Pasteur de Lille, U1011 - recepteurs nucleaires, maladies cardiovasculaires et diabete,, Universite de Lille, Lille, France.
Dept. Medicine Research, Div. of Gastroenterology, Hepatology and Nutrition Research, Childrens' University Hospital, Boston, MA.
St. John's Institute of Dermatology; Division of Genetics & Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London; NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London; London, UK.
Charles University in Prague
Pharmacology and Experimental Therapeutics Unit, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Swiss Institute of Allergy and Asthma Research, Molecular Immunology, Davos, Switzerland.
Utrecht University
Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan.

Research output: Contribution to journal › Article › peer-review

54 Citations (Scopus)

303 Downloads (Pure)

Abstract

While desired for the cure of allergy, regulatory immune cell subsets and non-classical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines. This article is protected by copyright. All rights reserved.

Original language	English
Pages (from-to)	328–340
Journal	Allergy
Volume	73
Issue number	2
Early online date	5 Oct 2017
DOIs	https://doi.org/10.1111/all.13311
Publication status	Published - Feb 2018

Keywords

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/all.13311Licence: CC BY

AllergoOncology Opposite Outcomes of_JENSEN-JAROLIM_Firstonline5October2017_GOLD VoR (CC BY)Final published version, 899 KBLicence: CC BY

Cite this

Jensen-Jarolim, E., Bax, H. J., Bianchini, R., Crescioli, S., Daniels-Wells, T. R., Dombrowicz, D., Fiebiger, E., Gould, H. J., Irshad, S., Janda, J., Josephs, D. H., Levi-Schaffer, F., O Mahony, L., Pellizzari, G., Penichet, M. L., Redegeld, F., Roth-Walter, F., Singer, J., Untersmayr, E., ... Karagiannis, S. N. (2018). AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer. Allergy, 73(2), 328–340. https://doi.org/10.1111/all.13311

@article{ef5bc16b091047b895ce6461770c268e,

title = "AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer",

abstract = "While desired for the cure of allergy, regulatory immune cell subsets and non-classical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines. This article is protected by copyright. All rights reserved.",

keywords = "Journal Article",

author = "E Jensen-Jarolim and Bax, {H J} and R Bianchini and S Crescioli and Daniels-Wells, {T R} and D Dombrowicz and E Fiebiger and Gould, {H J} and S Irshad and J Janda and Josephs, {D H} and F Levi-Schaffer and {O Mahony}, L and G Pellizzari and Penichet, {M L} and F Redegeld and F Roth-Walter and J Singer and E Untersmayr and L Vangelista and Karagiannis, {S N}",

year = "2018",

month = feb,

doi = "10.1111/all.13311",

language = "English",

volume = "73",

pages = "328–340",

journal = "Allergy",

issn = "0105-4538",

publisher = "Blackwell Publishing",

number = "2",

}

Jensen-Jarolim, E, Bax, HJ, Bianchini, R, Crescioli, S, Daniels-Wells, TR, Dombrowicz, D, Fiebiger, E, Gould, HJ , Irshad, S, Janda, J, Josephs, DH, Levi-Schaffer, F, O Mahony, L, Pellizzari, G, Penichet, ML, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, E, Vangelista, L & Karagiannis, SN 2018, 'AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer', Allergy, vol. 73, no. 2, pp. 328–340. https://doi.org/10.1111/all.13311

TY - JOUR

T1 - AllergoOncology

T2 - Opposite Outcomes of Immune Tolerance in Allergy and Cancer

AU - Jensen-Jarolim, E

AU - Bax, H J

AU - Bianchini, R

AU - Crescioli, S

AU - Daniels-Wells, T R

AU - Dombrowicz, D

AU - Fiebiger, E

AU - Gould, H J

AU - Irshad, S

AU - Janda, J

AU - Josephs, D H

AU - Levi-Schaffer, F

AU - O Mahony, L

AU - Pellizzari, G

AU - Penichet, M L

AU - Redegeld, F

AU - Roth-Walter, F

AU - Singer, J

AU - Untersmayr, E

AU - Vangelista, L

AU - Karagiannis, S N

PY - 2018/2

Y1 - 2018/2

N2 - While desired for the cure of allergy, regulatory immune cell subsets and non-classical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines. This article is protected by copyright. All rights reserved.

AB - While desired for the cure of allergy, regulatory immune cell subsets and non-classical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines. This article is protected by copyright. All rights reserved.

KW - Journal Article

UR - http://10.1111/all.13311

UR - http://www.scopus.com/inward/record.url?scp=85040675651&partnerID=8YFLogxK

U2 - 10.1111/all.13311

DO - 10.1111/all.13311

M3 - Article

C2 - 28921585

SN - 0105-4538

VL - 73

SP - 328

EP - 340

JO - Allergy

JF - Allergy

IS - 2

ER -

AllergoOncology: Opposite Outcomes of Immune Tolerance in Allergy and Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this